BeiGene, Ltd. (BEIGF)

OTCMKTS · Delayed Price · Currency is USD
15.50
0.00 (0.00%)
At close: Sep 3, 2024
-1.27%
Market Cap 21.52B
Revenue (ttm) 3.10B
Net Income (ttm) -523.70M
Shares Out n/a
EPS (ttm) -5.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 130
Open 15.50
Previous Close n/a
Day's Range 15.50 - 15.50
52-Week Range 11.00 - 16.58
Beta 0.62
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 10,600
Stock Exchange OTCMKTS
Ticker Symbol BEIGF
Full Company Profile

Financial Performance

In 2023, BeiGene's revenue was $2.46 billion, an increase of 73.65% compared to the previous year's $1.42 billion. Losses were -$881.71 million, -56.00% less than in 2022.

Financial Statements

News

There is no news available yet.